^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EML4-ALK C1156Y

    i
    Other names: EML4, EMAP Like 4, Restrictedly Overexpressed Proliferation-Associated Protein, Echinoderm Microtubule-Associated Protein-Like 4, Echinoderm Microtubule Associated Protein Like 4, Ropp 120, C2orf2, EMAP-4, EMAPL4, ROPP120, ELP120, NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
    Entrez ID:
    238; 27436
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    1year
    Characterization of TKI-induced drug-tolerant persister cells from a patient-derived cell line (AACR 2023)
    The model is a non-small cell lung cancer harboring EML4-ALK fusion and ALK C1156Y/G1269A mutation, sensitive to the 3rd generation ALK TKI lorlatinib... We demonstrated potential targetable features of DTP cells. A combination of targeted therapies with DTP drug candidates could represent a therapeutic opportunity to improve the depth of response and delay the emergence of resistance in patients.
    Preclinical
    |
    ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    EML4-ALK fusion • ALK fusion • ALK mutation • ALK C1156Y • ALK G1269A • EML4-ALK C1156Y • EML4-ALK G1269A • CDKN1B expression
    |
    Lorbrena (lorlatinib)
    3years
    [VIRTUAL] Patient-derived lung cancer organoids for the selection of therapeutic options in an ALK-rearranged tumor. (ASCO 2021)
    One patient was deemed as sensitive to carboplatin but tumor showed to be resistant...The patient started alectinib but showed progression after 12 months...Treatment was switched to brigatinib with no response...The In vitro results demonstrated no activity of lorlatinib but a strong response to crizotinib... We present clinical evidence that PDOs are an alternative tool in oncogenic addicted tumors helping to guide treatment decisions and increasing a more personalized sequential treatment approach.
    Clinical • IO biomarker
    |
    ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • EML4 (EMAP Like 4)
    |
    TP53 mutation • ALK rearrangement • EML4-ALK fusion • ALK fusion • ALK C1156Y • ALK I1171T • ALK I1171 • ALK V3a • EML4-ALK C1156Y • EML4-ALK I1171T • EML4-ALK variant 3a
    |
    Xalkori (crizotinib) • carboplatin • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • Alunbrig (brigatinib)